Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI4736 + Tremelimumab in Advanced Solid Tumors
NCT02261220Phase 1Completed
- Sponsor
- MedImmune
- Start
- Oct 2014
- Primary completion
- Jan 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 9
01
Overview
Phase 1, open-label, single-arm trial of durvalumab and tremelimumab in solid tumor (advanced stage), sponsored by MedImmune. Primary endpoints: Number of subjects reporting adverse events, Number of subjects reporting serious adverse events and 5 more. Started Oct 2014; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02261220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02261220.